These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26205198)

  • 1. Structural Requirements of Some 2-(1-Propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide Derivatives as Poly (ADP-Ribose) Polymerase (PARP) for the Treatment of Cancer: QSAR Approach.
    Sharma MC
    Interdiscip Sci; 2016 Mar; 8(1):11-22. PubMed ID: 26205198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural requirements of some 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide derivatives as poly (ADP-ribose) polymerase (PARP) for the treatment of cancer: QSAR approach.
    Sharma MC
    Interdiscip Sci; 2014 Sep; ():. PubMed ID: 25183353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QSAR study of 2-(1-Propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide as PARP inhibitors for treatment of cancer.
    Riahi S; Pourbasheer E; Dinarvand R; Ganjali MR; Norouzi P
    Chem Biol Drug Des; 2008 Dec; 72(6):575-84. PubMed ID: 19090924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
    Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
    Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular modeling studies on benzimidazole carboxamide derivatives as PARP-1 inhibitors using 3D-QSAR and docking.
    Zeng H; Zhang H; Jang F; Zhao L; Zhang J
    Chem Biol Drug Des; 2011 Sep; 78(3):333-52. PubMed ID: 21585709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.
    Penning TD; Zhu GD; Gandhi VB; Gong J; Thomas S; Lubisch W; Grandel R; Wernet W; Park CH; Fry EH; Liu X; Shi Y; Klinghofer V; Johnson EF; Donawho CK; Frost DJ; Bontcheva-Diaz V; Bouska JJ; Olson AM; Marsh KC; Luo Y; Rosenberg SH; Giranda VL
    Bioorg Med Chem; 2008 Jul; 16(14):6965-75. PubMed ID: 18541433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.
    Yeong KY; Tan SC; Mai CW; Leong CO; Chung FF; Lee YK; Chee CF; Abdul Rahman N
    Chem Biol Drug Des; 2018 Jan; 91(1):213-219. PubMed ID: 28719017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple receptor conformation docking, dock pose clustering and 3D QSAR studies on human poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
    Fatima S; Jatavath MB; Bathini R; Sivan SK; Manga V
    J Recept Signal Transduct Res; 2014 Oct; 34(5):417-30. PubMed ID: 25046176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors.
    Chen X; Huan X; Liu Q; Wang Y; He Q; Tan C; Chen Y; Ding J; Xu Y; Miao Z; Yang C
    Eur J Med Chem; 2018 Feb; 145():389-403. PubMed ID: 29335205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel and orally active poly(ADP-ribose) polymerase inhibitor, KR-33889 [2-[methoxycarbonyl(4-methoxyphenyl) methylsulfanyl]-1H-benzimidazole-4-carboxylic acid amide], attenuates injury in in vitro model of cell death and in vivo model of cardiac ischemia.
    Oh KS; Lee S; Yi KY; Seo HW; Koo HN; Lee BH
    J Pharmacol Exp Ther; 2009 Jan; 328(1):10-8. PubMed ID: 18836068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1
    Min R; Wu W; Wang M; Tang L; Chen D; Zhao H; Zhang C; Jiang Y
    Molecules; 2019 May; 24(10):. PubMed ID: 31108884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
    Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
    J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase.
    White AW; Almassy R; Calvert AH; Curtin NJ; Griffin RJ; Hostomsky Z; Maegley K; Newell DR; Srinivasan S; Golding BT
    J Med Chem; 2000 Nov; 43(22):4084-97. PubMed ID: 11063605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.
    Penning TD; Zhu GD; Gong J; Thomas S; Gandhi VB; Liu X; Shi Y; Klinghofer V; Johnson EF; Park CH; Fry EH; Donawho CK; Frost DJ; Buchanan FG; Bukofzer GT; Rodriguez LE; Bontcheva-Diaz V; Bouska JJ; Osterling DJ; Olson AM; Marsh KC; Luo Y; Giranda VL
    J Med Chem; 2010 Apr; 53(8):3142-53. PubMed ID: 20337371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of potential anti-tumor PARP-1 inhibitors by QSAR and molecular modeling studies.
    Abbasi-Radmoghaddam Z; Riahi S; Gharaghani S; Mohammadi-Khanaposhtanai M
    Mol Divers; 2021 Feb; 25(1):263-277. PubMed ID: 32140890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.
    Muñoz-Gámez JA; López Viota J; Barrientos A; Carazo Á; Sanjuán-Nuñez L; Quiles-Perez R; Muñoz-de-Rueda P; Delgado Á; Ruiz-Extremera Á; Salmerón J
    Liver Int; 2015 Apr; 35(4):1430-41. PubMed ID: 24821649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular docking and 3D-QSAR studies on inhibitors of DNA damage signaling enzyme human PARP-1.
    Fatima S; Bathini R; Sivan SK; Manga V
    J Recept Signal Transduct Res; 2012 Aug; 32(4):214-24. PubMed ID: 22713102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
    Halder AK; Saha A; Saha KD; Jha T
    J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of ( R)-Boc-2-methylproline via a Memory of Chirality Cyclization. Application to the Synthesis of Veliparib, a Poly(ADP-ribose) Polymerase Inhibitor.
    Kolaczkowski L; Barkalow J; Barnes DM; Haight A; Pritts W; Schellinger A
    J Org Chem; 2019 Apr; 84(8):4837-4845. PubMed ID: 30716275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of the PARP (poly ADP-ribose polymerase) inhibitor 2-(1-(4,4-difluorocyclohexyl)piperidin-4-yl)-1H-benzo[d]imidazole-4-carboxamide for the treatment of cancer.
    Tang L; Wu W; Zhang C; Shi Z; Chen D; Zhai X; Jiang Y
    Bioorg Chem; 2021 Sep; 114():105026. PubMed ID: 34186467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.